Open-Label Ponsegromab Appears Effective in Cancer-Associated Cachexia

Ponsegromab treatment over 64 weeks resulted in sustained improvements in body weight and suppression of growth differentiation factor 15 (GDF-15), a stress-induced cytokine, irrespective of prior treatment assignment, with a consistent…